Diversion, misuse and trafficking of methadone and buprenorphine

Similar documents
Diversion, Misuse and Trafficking of Methadone and Buprenorphine in the US and Europ

Postmarketing Surveillance of Prescription Drug Abuse

Prescription Opioid Dependence and Addiction: Experience in the United States

A National Perspective on the Abuse and Diversion of Prescription Drugs

Abuse, Misuse, and Diversion of Prescription Opioids: Evaluating the Problem and Proposed Solutions

Prescription Drug Abuse: Colorado and Nationwide

Richard C. Dart, MD, PhD Executive Director, RADARS System Denver Health and Hospital Authority

RADARS System International Pre-Symposium 11 May Global Insights in Prescription Drug Misuse

The Evolution of Abuse Deterrent Drug Formulations: Testing Effectiveness from the Benchtop to the Real World

Challenges in Conducting Postmarketing Abuse Investigations

Key points. o Potential for nonmedical use, abuse, and diversion of new products

Evolution of the Opioid Epidemic

Category 4 Can we prove that ADF opioids really are?

Key points. Background

Opioid Analgesics with Abuse- Deterrent Properties: Current Data and Future Opportunities

Evolution of the Opioid Epidemic

Interventions in Prescription Opioid Abuse Do (or can) Prescription Monitoring Programs Make a Difference?

Effect of Abuse-Deterrent Formulations and IR Opioids on Abuse, Overdose and Death from Rx Opioids

Trends in Opioid Analgesic Abuse and Mortality in Europe

Mosaic approach for monitoring Healthy People 2020 objectives:

Trends in Opioid Analgesic Abuse and Mortality in the United States

A Toxicologists View of Addiction

pharmacoepidemiology and drug safety 2009; 18: ORIGINAL REPORT

Gabapentin diversion and misuse in the United States from a law enforcement perspective: Diversion rates and qualitative research findings

Systematic Surveillance of Illicitly Manufactured Fentanyl Cases Initiated by Law Enforcement Steven P. Kurtz, PhD and Mance E.

Post-Marketing Surveillance: Lessons Learned and Recommendations for the Future

Setting the Stage: Are Abuse-Deterrent Opioids Formulations Ready for Prime Time?

Identification of Specific Drugs and Drug Diversion in Drug Overdose Fatalities

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

RADARS R SYSTEM INTERNATIONAL PRE-SYMPOSIUM. International Landscape of Prescription Medication Misuse

PRESCRIPTION DRUG MONITORING PROGRAM

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Opioid Prescription and Illicit Drug Overdoses: On the Rise

ARKANSAS DEPARTMENT OF HEALTH

Original Research Article Do Prescription Monitoring Programs Impact State Trends in Opioid Abuse/Misuse?pme_

Opioid Deaths Quadruple Since 1999

Policy and Political Dynamics of the Opioid Addiction Crisis in the United States

Gabapentin diversion and misuse: Data from law enforcement and substance users

Carefirst. +.V Family of health care plans

Pharmacy Medical Necessity Guidelines: Opioid Analgesics

Opioid Harm Reduction

Opioid Treatment in North Carolina SEPTEMBER 13, 2016

Prescription Drug Monitoring Program Update. Rebecca R. Poston, BPharm., MHL Program Manager August 26, 2017

Drug and Alcohol Dependence

Substance Abuse in US and Europe

Frontline Florida: Emerging Drug Trends The Opiate Epidemic

The Epidemiology of Opioid Abuse Thomas Dobbs, MD, MPH 6/30/2017

VIRGINIA DEPARTMENT OF HEALTH OFFICE OF THE CHIEF MEDICAL EXAMINER

20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days

Fentanyl, Opioid Overdose and Naloxone

2004-L SEPTEMBER

Opiate Use among Ohio Medicaid Recipients

PRESCRIPTION DRUG MONITORING PROGRAM ST. CHARLES COUNTY Q1 2018

National Institute on Drug Abuse

Buprenorphine pharmacology

A LOOK AT ABUSE-DETERRENT OPIOIDS

Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017

Long-Acting Opioid Analgesics

Opioid Prescribing Guidelines for Patients in the Emergency Department

Long-Acting Opioid Analgesics

NYSHFA/NYSCAL 16 th Annual Nurse Leadership Conference. Timothy J. Dewey Sr. Investigator NYS Bureau of Narcotic Enforcement.

A nation in pain: Focus on Medicaid

Hydrocodone 10mg vs oxycodone 10 mg. What is the difference between oxycontin and oxycodone hcl 1 acetaminophen with oxycodone and roxicodone 5mg

Long-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018

Montgomery County Poisoning Death Review, 2016: Quarter I Updated June 20, 2016

Appendix A. Socio-demographic Characteristics of Survey Respondents Compared to Current Population Survey (2013) Data

15 mg morphine 10 mg hydrocodone

CAN YOU INJECT A G77 OPANA

Opioid Analgesics. Recommended starting dose for opioid-naïve patients

Ingham County Opioid Surveillance

Proposed Changes to Existing Measure for HEDIS : Use of Opioids at High Dosage (UOD)

Opioid Overdose in Oregon Report to the Legislature

Recognizing Narcotic Abuse and Addiction and Helping Those With It

The Epidemiology of Opioid Abuse. Thomas Dobbs, MD, MPH Mississippi State Department of Health

JEANIE JARAMILLO-STAMETZ, PHARMD

Drug and Opioid Epidemic Report

Alberta Health. Opioids and Substances of Misuse. Alberta Report, 2017 Q3

25/03/2014. Workshop Overview. Hot Topics in FDA Regulations and Pharmacotherapy Research that Impact Patient Care:

SAFE OPIOID PRESCRIBING C.U.R.E.S. PROGRAM

Understanding and Combating the Heroin Epidemic

RAPID Analysis of Routes of Administration: Oral to Non-Oral Transitions

Medication Assisted Treatment. Michael Palladini, RPh MBA CAC

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A

Kentucky All Schedule Prescription Electronic Reporting (KASPER)

The Latest Prescription Trends for Controlled Prescription Drugs

Opioid Management of Chronic (Non- Cancer) Pain

IN THE CIRCUIT COURT OF BALDWIN COUNTY, ALABAMA

Generic Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE

USE OF OPIODS AT HIGHER DOSES IN PERSONS WITHOUT CANCER: MORPHINE EQUIVALENT DOSE EDIT

The Unseen Consequences of Prescription Drug Abuse. Stephen Loyd, M.D.

Aligning Market Objectives and Policy for National Public Health

Opana 15 mg street price new formulation

Pediatric Toxicology Update

2017 Drug Use Trends in King County, Washington

Opioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory

Drug Name (specify drug) Quantity Frequency Strength

Prescribing Opioids in the Opioid Epidemic. Scott Woffinden, PA-C Jason Chapman, JD

The Opioid and Heroin Overdose Epidemic in Virginia

Drug Trends &Trafficking I/S Brian Dempsey

What is an opioid? What do opioids do? Why is there an opioid overdose crisis? What is fentanyl? What about illicit or bootleg fentanyls?

Transcription:

Diversion, misuse and trafficking of methadone and buprenorphine Global Addiction Conference Richard C. Dart, MD, PhD Professor, University of Colorado

Prescription Opioid Deaths are Rising Internationally United Kingdom Drug Related Deaths 21-211 Source: RADARS System, Denver Health and Hospitals

What is the RADARS System? History 26, Denver Health and Hospital Authority (DHHA) Multiple pharmaceutical subscribers Independent program Denver Public Safety Net Hospital for 15 years State sanctioned independent authority Conflict of Interest Statement None, other than running system for DHHA as noted above. 3

RADARS System Scientific Advisory Board Principal Investigators Theodore J. Cicero, PhD Washington University at St. Louis Richard C. Dart, MD, PhD Denver Health and Hospital Authority Hilary Surratt, PhD Nova Southeastern University Mark W. Parrino, MPA American Association for the Treatment of Opioid Dependence Substance Abuse Experts Herbert D. Kleber, MD Columbia University Sidney Schnoll, MD, PhD Pinney Associates George E. Woody, MD University of Pennsylvania Epidemiology/Biostatistics Edgar Adams, ScD Covance Law Enforcement John Burke National Association of Drug Diversion Investigators Nabarun Dasgupta, MPH Founder Epidemico Alvaro Muñoz, PhD Johns Hopkins University 4

Challenges of Prescription Drug Abuse Surveillance Clandestine behavior Geographical variability Changes rapidly Multiple age groups Product specificity 15 active pharmaceutial ingredients (API) Opioids: Hydrocodone, oxycodone, hydromorphone, oxymorphone, morphine, fentanyl, tapentadol, tramadol, buprenorphine, methadone Stimulants Dozens of specific products (OxyContin, Opana, Suboxone, Subutex, etc.)

RADARS System Mosaic Acute Events 53 Poison Centers 46 States Drug Transactions Criminal Justice 28 investigator 5 states Entering Treatment OTP 73 programs 33 states Entering Treatment SKIP 125 practices 5 states New Initiates College Survey 2 students 5 States Illicit Market Price StreetRx.com Users/Buyers 5 states

RADARS System Process A Tale of Two Denominators Drug Diversion Poison Center OTP SKIP College Survey Numerators compiled by each program POPULATION RATE = Event Count by Area Population Disease burden on population Does not account for drug availability UNIQUE RECIPIENTS OF DISPENSED DRUG (URDD) RATE Event Count by Area = URDD URDD = Number of unique people filling prescription for drug (refills excluded) 7

TRENDS IN PRESCRIPTION OPIOID ABUSE IN THE UNITED STATES 8

Overall Opioid Abuse Trends in United States Population Rates, 22-212 1 Population Rate 5 Availability Rate (URDD).8.6.4.2 22 27 212 22 27 212 Poison Center Drug Diversion SKIP OTP 9

RADARS System Opioid Abuse Trends URDD Rates (Ranked Highest-Lowest) 212 Rank Poison Center Opioid Treatment Survey of Key Informant Pts Drug Diversion 1 Methadone Oxymorphone Oxymorphone Oxymorphone 2 Oxymorphone Methadone Hydromorphone Hydromorphone 3 Buprenorphine Hydromorphone Methadone Methadone 4 Hydromorphone Buprenorphine Buprenorphine Buprenorphine 5 Morphine Morphine Morphine Morphine 6 Fentanyl Fentanyl Fentanyl Oxycodone 7 Tramadol Tapentadol Tapentadol Fentanyl 8 Oxycodone Oxycodone Oxycodone Hydrocodone 9 Tapentadol Hydrocodone Hydrocodone Tramadol 1 Hydrocodone Tramadol Tramadol Tapentadol 1

BUPRENORPHINE AND METHADONE ABUSE IN THE US

How Many Patients Fill a Prescription for Methadone? Unique Recipients of dispensed drug (URDD) 29Q1-212Q4 Methadone Combination Buprenorphine Tablets SI Buprenorphine Tablets Combination Buprenorphine Film 291 292 293 294 211 212 213 214 2111 2112 2113 2114 2121 2122 2123 2124

Buprenorphine Data Comparison RADARS System & CESAR Fax 12 RADARS System Drug Diversion Program Diversion Reports 22-212 1 Diversion reports 8 6 4 2 Total Buprenorphine Total Methadone 22 23 24 25 26 27 28 29 21 211 212 CESAR = Center for Substance Abuse Research 13

Opioid Treatment Program Past 3 Day Endorsements, 29-212 Population rate 1, 1.4 1.2 1.8.6.4.2 Population Rate Methadone high, but decreasing Bup-Single Ingredient Increasing Bup-Naloxone Film Strip increasing slightly Bup-Naloxone Combination Decreasing Slightly URDD rate per 1, 9 8 7 6 5 4 3 2 1 Availability Rate (URDD) 291 292 293 294 211 212 213 214 2111 2112 2113 2114 2121 2122 2123 2124 Bup-Single Ingredient Highest, Increased, Flat Methadone Decreasing Bup-Naloxone Combination Lower, Flat Bup-Naloxone Film Strip Lowest, Decreasing

Survey of Key Informant Patients Past 3 Day Endorsements, 29-212 Population per 1, URDD rate per 1,.7.6.5.4.3.2.1 7 6 5 4 3 2 1 Population Rate Availability Rate (URDD) 291 292 293 294 211 212 213 214 2111 2112 2113 2114 2121 2122 2123 2124 Methadone high, but decreasing Bup-Single Ingredient Increasing Bup-Naloxone Combination Increasing Flat Bup-Naloxone Film Strip Increasing slightly Bup-Single Ingredient Increasing Dramatically Methadone Slight Decrease Bup-Naloxone Combination Increasing Bup-Naloxone Film Strip low, flat

RADARS System Drug Diversion Cases 29-212 URDD rate per 1, Population rate per 1,.25.2.15.1.5 2.5 2 1.5 1.5 Population Rate Availability Rate (URDD) Methadone high, but decreasing slightly Bup-Naloxone Combination Decreasing Slightly Bup-Naloxone Film Strip Increasing Bup-Single Ingredient Increasing Bup-Naloxone Combination Increasing Greatly Bup-Single Ingredient Increasing Greatly Methadone Slight Decrease 291 292 293 294 211 212 213 214 2111 2112 2113 2114 2121 2122 2123 2124 Bup-Naloxone Film Strip increasing slightly

StreetRx www.streetrx.com Population Any person in US with access to the internet Definition/Type of Cases Utilize crowdsourcing methodology to calculate average price of specific prescription drug in particular location Validated by DD Coverage All 5 states 17

Comparison of StreetRx, RADARS System Drug Diversion and Silk Road Dasgupta, Suratt, et al, manuscript submitted 18

Death Cases in Poison Center Program All Ages, 29Q1-212Q4 5 45 4 35 3 25 2 15 1 5 29 21 211 212 Total Methadone Total Combination Buprenorphine Tablets Total Single Ingredient Buprenorphine Tablets Total Buprenorphine Oral Films

Death Cases in Poison Center Program Ages under 12 years, 29Q1-212Q4 4 3 Total Methadone 2 1 29 21 211 212 Total Combination Buprenorphine Tablets Total Single Ingredient Buprenorphine Tablets Total Buprenorphine Oral Films

.8 Poison Center Program Intentional Abuse Exposures of Opana ER 1 st Quarter 29 through 3 rd Quarter 212 Rate per 1, URDD.7.6.5.4.3.2 Introduction of OxyContin ORF Total Oxymorphone Pre ADF Post ADF.1 Year/Quarter 21

Conclusions Prescription opioid abuse in the US may be plateauing, but still causes 16, deaths per year Methadone Endorsements in treatment programs decreasing More deaths than any other opioid But most deaths involve pills (treatment of pain) Buprenorphine Abuse is increasing quickly perhaps due to generic availability Single-ingredient Subutex Combination tablet (Bup-naloxone; Suboxone ) Exceptional safety in all groups Abuse of buprenorphine strip has been very low Why is the price of buprenorphine so high?

Thank you!